pembrolizumab,bevacizumab
merck,roche
['kn826', ' bev ', 'pembro']
2. #kn826, pembro was approved with chemo +/- bev for metastatic cervical cancer patients with pd-l1 cps 1. update: - os in cps 1, 28.6 vs 16.5 months (hr 0.60)
- pfs in cps 1 (hr 0.58) and overall population (hr 0.61) #asco23 3/4 
Practice changing 🗣 for community oncologists: w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @WilmotCancer. Views are our own. COI: https://t.co/cJOjp0RvQE